MRA Advisory Group Sells 313 Shares of Amgen Inc. $AMGN

MRA Advisory Group decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 995 shares of the medical research company’s stock after selling 313 shares during the period. MRA Advisory Group’s holdings in Amgen were worth $278,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of AMGN. Livelsberger Financial Advisory acquired a new position in shares of Amgen during the second quarter worth $49,000. NBC Securities Inc. increased its position in shares of Amgen by 11.4% during the second quarter. NBC Securities Inc. now owns 7,435 shares of the medical research company’s stock worth $2,075,000 after purchasing an additional 761 shares in the last quarter. Apella Capital LLC increased its position in shares of Amgen by 33.0% during the second quarter. Apella Capital LLC now owns 1,773 shares of the medical research company’s stock worth $519,000 after purchasing an additional 440 shares in the last quarter. Heartwood Wealth Advisors LLC increased its position in shares of Amgen by 5.5% during the second quarter. Heartwood Wealth Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $1,344,000 after purchasing an additional 253 shares in the last quarter. Finally, Legacy Private Trust Co. increased its position in shares of Amgen by 13.6% during the second quarter. Legacy Private Trust Co. now owns 9,456 shares of the medical research company’s stock worth $2,640,000 after purchasing an additional 1,134 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $276.39 on Monday. Amgen Inc. has a one year low of $253.30 and a one year high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market cap of $148.80 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 2.40 and a beta of 0.49. The firm’s fifty day moving average is $292.54 and its two-hundred day moving average is $291.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the prior year, the company earned $4.97 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio is 77.84%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. UBS Group reduced their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Citigroup upped their price target on Amgen from $305.00 to $310.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Piper Sandler upped their price target on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research report on Monday, August 25th. Finally, Bank of America upped their target price on Amgen from $252.00 to $261.00 and gave the company an “underperform” rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $304.43.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.